Persones / Equip Humà

Manuel Vázquez Carrera

Buscador de publicacions

Publicacions

  • Codony S, Pujol E, Pizarro J, Feixas F, Valverde E, Loza MI, Brea JM, Saez E, Oyarzabal J, Pineda-Lucena A, Pérez-Dueñas B, Pérez C, Rodríguez-Franco MI, Leiva R, Osuna S, Morisseau C, Hammock BD, Vazquez M and Vázquez S.

    2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors: In Vivo Evaluation in a Murine Model of Acute Pancreatitis

    JOURNAL OF MEDICINAL CHEMISTRY . 63(17): 9237-9257. Nº de cites: 19

    [doi:10.1021/acs.jmedchem.0c00310]

  • Barroso E, Rodríguez-Rodríguez R, Zarei M, Pizarro-Degado J, Planavila A, Palomer FX, Villarroya-Gombau F and Vazquez M.

    SIRT3 deficiency exacerbates fatty liver by attenuating the HIF1 alpha-LIPIN 1 pathway and increasing CD36 through Nrf2

    CELL COMMUNICATION AND SIGNALING . 18(1): 147-147. Nº de cites: 27

    [doi:10.1186/s12964-020-00640-8]

  • Zarei M, Pizarro J, Barroso E, Palomer FX and Vazquez M.

    Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis

    TRENDS IN PHARMACOLOGICAL SCIENCES . 41(3): 199-208. Nº de cites: 69

    [doi:10.1016/j.tips.2019.12.005]

  • Palomer FX, Román-Azcona MS, Pizarro J, Planavila A, Villarroya-Gombau F, Valenzuela-Alcaraz BI, Crispi F, Sepúlveda-Martínez Á, Miguel-Escalada I, Ferrer J, Nistal JF, García R, Davidson MM, Barroso E and Vazquez M.

    SIRT3-mediated inhibition of FOS through histone H3 deacetylation prevents cardiac fibrosis and inflammation.

    signal transduction and targeted therapy . 5(1): 14-14. Nº de cites: 112

    [doi:10.1038/s41392-020-0114-1]

  • Puigoriol-Illamola D, Leiva R, Vazquez M, Vázquez S, Griñán-Ferré C and Pallàs M.

    11 beta-HSD1 Inhibition Rescues SAMP8 Cognitive Impairment Induced by Metabolic Stress

    MOLECULAR NEUROBIOLOGY . 57(1): 551-565. Nº de cites: 10

    [doi:10.1007/s12035-019-01708-4]

  • Márquez A, Aymerich J, Dei M, Rodríguez-Rodríguez R, Vazquez M, Pizarro J, Giménez-Gómez P, Merlos Á, Terés L, Serra-Graells F, Jiménez-Jorquera C, Domínguez C and Muñoz-Berbel X.

    Reconfigurable multiplexed point of Care System for monitoring type 1 diabetes patients.

    BIOSENSORS & BIOELECTRONICS . 136: 38-46. Nº de cites: 13

    [doi:10.1016/j.bios.2019.04.015]

  • Rodríguez-Calvo R, Girona J, Rodríguez M, Samino S, Barroso E, de Gonzalo-Calvo D, Guaita-Esteruelas S, Heras M, van der Meer RW, Lamb HJ, Yanes O, Correig X, Llorente-Cortés V, Vazquez M and Masana L.

    Fatty acid binding protein 4 (FABP4) as a potential biomarker reflecting myocardial lipid storage in type 2 diabetes

    METABOLISM-CLINICAL AND EXPERIMENTAL . 96: 12-21. Nº de cites: 37

    [doi:10.1016/j.metabol.2019.04.007]

  • Zarei M, Pujol E, Quesada T, Villarroya-Gombau F, Barroso E, Vázquez S, Pizarro J, Palomer FX and Vazquez M.

    Oral administration of a new HRI activator as a new strategy to improve high-fat-diet-induced glucose intolerance, hepatic steatosis, and hypertriglyceridaemia through FGF21.

    BRITISH JOURNAL OF PHARMACOLOGY . 176(13): 2292-2305. Nº de cites: 14

    [doi:10.1111/bph.14678]

  • Zarei M, Barroso E, Palomer FX, Escolà-Gil JC, Cedó L, Wahli W and Vazquez M.

    Pharmacological PPARß/d activation upregulates VLDLR in hepatocytes.

    Clinica e Investigacion en Arteriosclerosis . 31(3): 111-118. Nº de cites: 11

    [doi:10.1016/j.arteri.2019.01.004]

  • Busquets O, Eritja À, López BM, Ettcheto M, Manzine PR, Castro-Torres RD, Verdaguer E, Olloquequi J, Vazquez M, Auladell C, Folch J and Camins A.

    Role of brain c-Jun N-terminal kinase 2 in the control of the insulin receptor and its relationship with cognitive performance in a high-fat diet pre-clinical model

    JOURNAL OF NEUROCHEMISTRY . 149(2): 255-268. Nº de cites: 6

    [doi:10.1111/jnc.14682]